Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines

Hong Ying Ruan, Muneyuki Masuda, Aya Ito, Kazuo Umezawa, Torahiko Nakashima, Ryuji Yasumatsu, Yuichiro Kuratomi, Tomoya Yamamoto, I. Bernard Weinstein, Shizuo Komune

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. Recent studies provide evidence that the constitutive activation of nuclear factor-kappa B, NF-κB, plays a critical role in enhancing the growth of several types of malignancies, including head and neck squamous cell carcinoma (HNSCC). Methods. In this study, we examined the effects of a newly synthesized NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, induction of apoptosis, gene expression, and chemosensitivity in two HNSCC cell lines (YCU-H891 and KB), which expressed high levels of nuclear NF-κB protein. Results. DHMEQ showed strong growth inhibitory effects on these two cell lines, with a 50% cell growth inhibition (IC50) concentration of approximately 20 μg/mL. These growth inhibitory effects were associated with inhibition of the NF-κB activity. Treatment with DHMEQ induced apoptosis in a dose-dependent manner accounting, at least in part, for the growth inhibition by DHMEQ. DHMEQ strongly inhibited cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells. In addition, low concentrations of DHMEQ (1.0 or 5.0 μg/mL) synergistically enhanced the cellular sensitivity of YCU-H and KB cells to cisplatin, which is a key chemotherapeutic agent in the treatment of HNSCC. Conclusions. These results suggest that DHMEQ may be effective when used alone or in combination with other agents in the treatment of HNSCC.

Original languageEnglish
Pages (from-to)158-165
Number of pages8
JournalHead and Neck
Volume28
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Apoptosis
Gene Expression
Cell Line
Growth
KB Cells
Cyclin D1
Vascular Endothelial Growth Factor A
NF-kappa B
Carcinoma, squamous cell of head and neck
dehydroxymethylepoxyquinomicin
Cisplatin
Inhibitory Concentration 50
Messenger RNA
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. / Ruan, Hong Ying; Masuda, Muneyuki; Ito, Aya; Umezawa, Kazuo; Nakashima, Torahiko; Yasumatsu, Ryuji; Kuratomi, Yuichiro; Yamamoto, Tomoya; Weinstein, I. Bernard; Komune, Shizuo.

In: Head and Neck, Vol. 28, No. 2, 02.2006, p. 158-165.

Research output: Contribution to journalArticle

Ruan, Hong Ying ; Masuda, Muneyuki ; Ito, Aya ; Umezawa, Kazuo ; Nakashima, Torahiko ; Yasumatsu, Ryuji ; Kuratomi, Yuichiro ; Yamamoto, Tomoya ; Weinstein, I. Bernard ; Komune, Shizuo. / Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. In: Head and Neck. 2006 ; Vol. 28, No. 2. pp. 158-165.
@article{e1d8c64e5b2f423fbf4ed9e1e88e80df,
title = "Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines",
abstract = "Background. Recent studies provide evidence that the constitutive activation of nuclear factor-kappa B, NF-κB, plays a critical role in enhancing the growth of several types of malignancies, including head and neck squamous cell carcinoma (HNSCC). Methods. In this study, we examined the effects of a newly synthesized NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, induction of apoptosis, gene expression, and chemosensitivity in two HNSCC cell lines (YCU-H891 and KB), which expressed high levels of nuclear NF-κB protein. Results. DHMEQ showed strong growth inhibitory effects on these two cell lines, with a 50{\%} cell growth inhibition (IC50) concentration of approximately 20 μg/mL. These growth inhibitory effects were associated with inhibition of the NF-κB activity. Treatment with DHMEQ induced apoptosis in a dose-dependent manner accounting, at least in part, for the growth inhibition by DHMEQ. DHMEQ strongly inhibited cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells. In addition, low concentrations of DHMEQ (1.0 or 5.0 μg/mL) synergistically enhanced the cellular sensitivity of YCU-H and KB cells to cisplatin, which is a key chemotherapeutic agent in the treatment of HNSCC. Conclusions. These results suggest that DHMEQ may be effective when used alone or in combination with other agents in the treatment of HNSCC.",
author = "Ruan, {Hong Ying} and Muneyuki Masuda and Aya Ito and Kazuo Umezawa and Torahiko Nakashima and Ryuji Yasumatsu and Yuichiro Kuratomi and Tomoya Yamamoto and Weinstein, {I. Bernard} and Shizuo Komune",
year = "2006",
month = "2",
doi = "10.1002/hed.20304",
language = "English",
volume = "28",
pages = "158--165",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines

AU - Ruan, Hong Ying

AU - Masuda, Muneyuki

AU - Ito, Aya

AU - Umezawa, Kazuo

AU - Nakashima, Torahiko

AU - Yasumatsu, Ryuji

AU - Kuratomi, Yuichiro

AU - Yamamoto, Tomoya

AU - Weinstein, I. Bernard

AU - Komune, Shizuo

PY - 2006/2

Y1 - 2006/2

N2 - Background. Recent studies provide evidence that the constitutive activation of nuclear factor-kappa B, NF-κB, plays a critical role in enhancing the growth of several types of malignancies, including head and neck squamous cell carcinoma (HNSCC). Methods. In this study, we examined the effects of a newly synthesized NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, induction of apoptosis, gene expression, and chemosensitivity in two HNSCC cell lines (YCU-H891 and KB), which expressed high levels of nuclear NF-κB protein. Results. DHMEQ showed strong growth inhibitory effects on these two cell lines, with a 50% cell growth inhibition (IC50) concentration of approximately 20 μg/mL. These growth inhibitory effects were associated with inhibition of the NF-κB activity. Treatment with DHMEQ induced apoptosis in a dose-dependent manner accounting, at least in part, for the growth inhibition by DHMEQ. DHMEQ strongly inhibited cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells. In addition, low concentrations of DHMEQ (1.0 or 5.0 μg/mL) synergistically enhanced the cellular sensitivity of YCU-H and KB cells to cisplatin, which is a key chemotherapeutic agent in the treatment of HNSCC. Conclusions. These results suggest that DHMEQ may be effective when used alone or in combination with other agents in the treatment of HNSCC.

AB - Background. Recent studies provide evidence that the constitutive activation of nuclear factor-kappa B, NF-κB, plays a critical role in enhancing the growth of several types of malignancies, including head and neck squamous cell carcinoma (HNSCC). Methods. In this study, we examined the effects of a newly synthesized NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, induction of apoptosis, gene expression, and chemosensitivity in two HNSCC cell lines (YCU-H891 and KB), which expressed high levels of nuclear NF-κB protein. Results. DHMEQ showed strong growth inhibitory effects on these two cell lines, with a 50% cell growth inhibition (IC50) concentration of approximately 20 μg/mL. These growth inhibitory effects were associated with inhibition of the NF-κB activity. Treatment with DHMEQ induced apoptosis in a dose-dependent manner accounting, at least in part, for the growth inhibition by DHMEQ. DHMEQ strongly inhibited cyclin D1 and vascular endothelial growth factor (VEGF) promoter activity and decreased the levels of cyclin D1 protein and VEGF mRNA in KB cells. In addition, low concentrations of DHMEQ (1.0 or 5.0 μg/mL) synergistically enhanced the cellular sensitivity of YCU-H and KB cells to cisplatin, which is a key chemotherapeutic agent in the treatment of HNSCC. Conclusions. These results suggest that DHMEQ may be effective when used alone or in combination with other agents in the treatment of HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=31444456450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444456450&partnerID=8YFLogxK

U2 - 10.1002/hed.20304

DO - 10.1002/hed.20304

M3 - Article

C2 - 16355386

AN - SCOPUS:31444456450

VL - 28

SP - 158

EP - 165

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 2

ER -